Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

UCB and Sanofi Partner for Innovation in Immune-Mediated Diseases

Published: Friday, March 14, 2014
Last Updated: Friday, March 14, 2014
Bookmark and Share
Goal is to identify novel small molecule therapies to address a wide range of immune-mediated diseases.

UCB and Sanofi have entered into a scientific and strategic collaboration for the discovery and development of innovative anti-inflammatory small molecules which have the potential to treat a wide range of immune-mediated diseases in areas such as gastroenterology and arthritis.

“We partner Sanofi’s significant expertise, strong capabilities and resources with UCB’s cutting-edge research skills and breakthrough innovations. Together we can maximize the opportunity to treat diseases currently treated by biologic agents with small molecules and thus benefit millions of people suffering from severe diseases,” commented Ismail Kola, President UCB NewMedicines.

“Immune-mediated diseases affect individuals, families, and communities and impact the economies of countries and nations, making this poorly understood category of diseases a significant public health burden,” said Dr. Elias Zerhouni, President, Global R&D at Sanofi. “Joining efforts with UCB, we will address a scientific challenge in immunology, and increase the chances of accelerating the discovery and development of future therapies.”

UCB NewMedicines, the research arm of UCB, have used an innovative approach to identify small molecules modulators of a biological pathway, for which parenterally administered biologic therapies have proven highly efficacious in patients. A dedicated team of scientists will be formed under the leadership of Sanofi and UCB, and will join forces in a discovery and development based collaboration to characterize and identify new potential therapies.

Under the terms of the agreement, Sanofi and UCB will share costs and profits on a 50/50 basis. UCB will be entitled to initial upfront, preclinical and clinical development milestone payments from Sanofi, potentially exceeding € 100 million.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

UCB Announces US and EU Regulatory Filings for Brivaracetam
Major milestone for brivaracetam is latest step towards UCB goal of extending treatment choices for adult epilepsy patients with uncontrolled partial-onset seizures.
Tuesday, January 27, 2015
Scientists Invited to Access New Cutting-edge Technology Platform
UCB announces that it has launched its ‘Technology Platform Access’, a collaboration programme for the discovery and development of novel antibodies against potential therapeutic targets.
Thursday, May 01, 2014
UCB Launches Strategic Research Alliance with Weill-Cornell Medical College
Strategic collaboration commences with three discovery programs in areas of high patient need.
Friday, April 04, 2014
UCB CEO to Chair IMI Board for a Second Term
Roch Doliveux to spearhead industry’s commitment to world’s biggest public-private partnership in biopharmaceutical research and innovation.
Wednesday, April 02, 2014
UCB and Biogen Idec Enter Agreement
Relationship leverages UCB’s expertise and presence in Asia to bring Biogen Idec’s innovative therapies to patients in new markets.
Friday, January 31, 2014
Online Challenge to Find Next Generation of Breakthrough Medicines
UCB announces the global launch of its ‘Innovation Challenge’ which seeks to find rare phenotypes.
Tuesday, January 28, 2014
Multimillion Pound Investment in UK Life Sciences Research and Development
UCB invests over £3 million in new bespoke cutting-edge robotic platform for UK R&D HQ.
Wednesday, December 11, 2013
UCB Receives CHMP Positive Opinion for Cimzia in Active PsA
Positive opinion is supported by data from the RAPID™-PsA study.
Monday, October 28, 2013
Vectura and UCB to Collaborate and Share Expertise in Severe Inflammatory
Collaboration for the development of an innovative biologic immunomodulatory product in the area of severe inflammatory.
Tuesday, October 01, 2013
UCB Announces Third Research Collaboration with Harvard University
New Research Alliance project to focus on human microbiome to develop new therapeutic applications in immunology.
Wednesday, October 10, 2012
UCB Announces Start of C-EARLY™ Study for Cimzia® in RA
Phase III study to evaluate Cimzia® (certolizumab pegol) in adult patients with early, active, moderate to severe rheumatoid arthritis who have not been exposed to disease-modifying antirheumatic drugs.
Thursday, August 23, 2012
New Real World Clinical Data Showed Vimpat® (lacosamide) Effective in Achieving Seizure Control
At final follow-up 31.1% patients reported =50% seizures reduction and 9.8% were seizure free.
Friday, July 06, 2012
UCB to Showcase Immunology Portfolio at EULAR 2012
Data to be presented on certolizumab pegol, epratuzumab and CDP7851/AMG 785.
Thursday, July 05, 2012
UCB and Domainex Collaboration Provides Valuable Information on Cancer Drug Target
New structural information allowed UCB scientists to design a novel class of molecules which inhibit MEK.
Thursday, March 15, 2012
UCB CEO to Chair Innovative Medicines Initiative Board
Roch Doliveux confirms industry’s commitment to unique EU public-private partnership.
Monday, March 12, 2012
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!